Enhanced	enhanced	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
beta-adrenoceptor	beta-adrenoceptor	O	O	O	O
antagonists	antagonists	O	O	O	O
in	in	O	O	O	O
rats	rats	O	O	O	O
pretreated	pretreated	O	O	O	O
with	with	O	O	O	O
isoniazid	isoniazid	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

High	high	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
isoniazid	isoniazid	CHEMICALS	O	OTHERS	I
increase	increase	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
vasodilators	vasodilators	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
change	change	O	O	O	O
the	the	O	O	O	O
accompanying	accompanying	O	O	O	O
reflex	reflex	O	O	O	O
tachycardia	tachycardia	O	DISEASE	OTHERS	I
to	to	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
an	an	O	O	O	O
interaction	interaction	O	O	O	O
attributed	attributed	O	O	O	O
to	to	O	O	O	O
decreased	decreased	O	O	O	O
synthesis	synthesis	O	O	O	O
of	of	O	O	O	O
brain	brain	O	O	O	O
gamma-aminobutyric	gamma-aminobutyric	O	O	O	O
acid	acid	O	O	O	O
(	(	O	O	O	O
GABA	gaba	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
possible	possible	O	O	O	O
enhancement	enhancement	O	O	O	O
by	by	O	O	O	O
isoniazid	isoniazid	CHEMICALS	O	OTHERS	I
of	of	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
beta-adrenoceptor	beta-adrenoceptor	O	O	O	O
antagonists	antagonists	O	O	O	O
was	was	O	O	O	O
determined	determined	O	O	O	O
in	in	O	O	O	O
rats	rats	O	O	O	O
anaesthetised	anaesthetised	O	O	O	O
with	with	O	O	O	O
chloralose-urethane	chloralose-urethane	O	O	O	O
.	.	O	O	O	O

Isoniazid	isoniazid	CHEMICALS	O	OTHERS	I
significantly	significantly	O	O	O	O
increased	increased	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
after	after	O	O	O	O
propranolol	propranolol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
pindolol	pindolol	O	O	OTHERS	I
,	,	O	O	O	O
labetalol	labetalol	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
atenolol	atenolol	O	O	OTHERS	I
,	,	O	O	O	O
as	as	O	O	O	O
well	well	O	O	O	O
as	as	O	O	O	O
after	after	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
after	after	O	O	O	O
hexamethonium	hexamethonium	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
carbachol	carbachol	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Enhancement	enhancement	O	O	O	O
was	was	O	O	O	O
not	not	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
rats	rats	O	O	O	O
pretreated	pretreated	O	O	O	O
with	with	O	O	O	O
methylatropine	methylatropine	O	O	OTHERS	I
or	or	O	O	O	O
previously	previously	O	O	O	O
vagotomised	vagotomised	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
are	are	O	O	O	O
compatible	compatible	O	O	O	O
with	with	O	O	O	O
interference	interference	O	O	O	O
by	by	O	O	O	O
isoniazid	isoniazid	CHEMICALS	O	OTHERS	I
with	with	O	O	O	O
GABAergic	gabaergic	O	O	O	O
inhibition	inhibition	O	O	O	O
of	of	O	O	O	O
cardiac	cardiac	O	O	O	O
parasympathetic	parasympathetic	O	O	O	O
tone	tone	O	O	O	O
.	.	O	O	O	O

Such	such	O	O	O	O
interference	interference	O	O	O	O
could	could	O	O	O	O
be	be	O	O	O	O
exerted	exerted	O	O	O	O
centrally	centrally	O	O	O	O
,	,	O	O	O	O
possibly	possibly	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
nucleus	nucleus	O	O	O	O
ambiguus	ambiguus	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
peripherally	peripherally	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
sinus	sinus	O	O	O	O
node	node	O	O	O	O
.	.	O	O	O	O

